Business context and reporting period
The filing is for Prestige Brands Holdings, Inc. (the registrant named in the filing; the request metadata says Prestige Consumer Healthcare). It covers the three months ended June 30, 2013—fiscal 2014 first quarter—and compares results with the three months ended June 30, 2012. The company markets and distributes over-the-counter healthcare and household cleaning products.
Key financial metrics
Unless otherwise noted, amounts are in millions of dollars. Income and cash-flow figures compare the year-earlier quarter; balance-sheet figures compare June 30, 2013 with March 31, 2013.
| Metric | June 2013 quarter / June 30, 2013 | Comparable / prior balance date |
|---|---|---|
| Total revenue | $143.0 | $147.0; down 2.7% |
| Gross profit and margin | $83.5; 58.4% | $83.6; 56.9% |
| Operating income and margin | $49.4; 34.6% | $43.8; 29.8% |
| Net income and diluted EPS | $20.7; $0.40 | $14.7; $0.29 |
| Operating cash flow | $22.8 | $14.7 |
| Cash and cash equivalents | $19.3 | $15.7 at March 31 |
| Current assets / current liabilities | $163.0 / $81.7 | $164.2 / $96.7 at March 31 |
| Debt principal / debt net of discount | $960.0 / $953.2 | $978.0 / $970.9 at March 31 |
Capital expenditures were $1.4 million. The company repaid $18.0 million on its revolving credit facility; it reported $80.0 million of remaining capacity under the $95.0 million facility. Working capital was approximately $81.2 million. The filing does not provide a clear actual leverage ratio.
Material changes versus the prior comparable period
- Revenue declined $4.0 million, primarily reflecting the Phazyme divestiture, timing of customer promotions, and lower prior-year-comparable cough-and-cold shipments. OTC Healthcare revenue fell 2.6%; Household Cleaning revenue fell 3.7%.
- Gross profit was nearly flat, while gross margin improved to 58.4% from 56.9%, which management attributed mainly to lower promotional spending. Segment contribution margin, a non-GAAP measure, rose 1.7% to $64.3 million; Household Cleaning improved, while OTC Healthcare declined.
- Operating income increased $5.6 million. General and administrative expense fell to $11.6 million from $16.2 million, mainly because the prior-year quarter included GSK brand transition and integration costs, legal and professional fees, and other costs.
- Interest expense declined to $15.9 million from $19.9 million as average debt was lower and borrowing costs decreased. Net income rose approximately 41% year over year.
- Operating cash flow increased by $8.1 million, supported by higher profitability and working-capital movements, including collections of receivables.
Outlook, commentary, risks and unusual items
- Management gave no overall revenue or earnings guidance in the filing. It expects a 38.3% effective tax rate for the remaining fiscal 2014 quarters, excluding discrete items, and expects depreciation and amortization to rise in the latter half of the year because of the ERP system implementation.
- Management expected revenue to face effects from competitive products returning to the market after recalls. It also cited competition, pricing and consumer trends, customer concentration, reliance on third-party manufacturers, raw-material and transportation costs, and distribution disruption as risks.
- On July 1, 2013, after quarter-end, the company acquired Care Pharmaceuticals Pty Ltd., an Australian healthcare-products business, funded with existing credit-facility borrowings and cash. The purchase price and acquisition-date fair values were not yet determined in the filing.
- Goodwill and intangible assets totaled $1.54 billion, a substantial portion of total assets. No impairment was recorded, but management noted that lower sales or margins, competition, consumer preference changes, or reduced advertising could lead to future impairment.
- Total principal debt was $960.0 million, including $460.0 million of variable-rate borrowings. The company reported covenant compliance at June 30, 2013. Debt agreements restrict certain actions and include cross-default provisions. Routine legal matters were not expected by management to have a material adverse effect.
- The filing states that a 1 percentage-point increase in variable borrowing rates would adversely affect pre-tax earnings and cash flows by approximately $3.4 million for the quarter; the period basis of this sensitivity is worth checking. Substantially all cash balances were uninsured at quarter-end.
Important facts for investors to verify
- Reconcile the revenue decline and margin improvement, including how promotional timing and the Phazyme divestiture affected comparability.
- Review debt maturities, variable-rate exposure, available revolver capacity, covenant headroom, and the stated interest-rate sensitivity.
- Assess the Care Pharmaceuticals acquisition’s purchase price, financing, integration requirements, and subsequent reported contribution.
- Monitor sales trends in the weaker product categories, major-customer concentration, and the return of competing products to the market.
- Evaluate the assumptions supporting the substantial goodwill and intangible-asset balances and the company’s estimates for promotional allowances, returns, and inventory obsolescence.